Can I read Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer on EtoBox?

Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer by Solange Peters; Alice T. Shaw; Benjamin Besse; Enriqueta Felip; Benjamin J. Solomon; Ross A. Soo; Alessandra Bearz; Shirish M. Gadgeel; Chia-Chi Lin; Steven Kao; Takashi Seto; Elizabeth T. Masters; Antonello Abbattista; Jill S. Clancy; Holger Thurm; Arlene Reisman; Gerson Peltz; D. Ross Camidge is a Medicine article available to read on EtoBox.

What is Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer about?

## Objectives: To evaluate patient-reported outcomes (pros) from a phase 1/2 study (nct01970865) in patients with anaplastic lymphoma kinase (alk)- or ros1-positive advanced non-small cell lung cancer (nsclc) treated with lorlatinib 100 mg once daily. ## Materials and methods: Pro measures, including global quality of life (qol), functioning domains and symptoms, were assessed by the european organisation for research and treatment of cancer (eortc) quality of life questionnaire core 30 (qlq-c30) and the 13-item lung cancer (qlq-lc13) module. mean changes of absolute scores from baseline were assessed. percentages of patients showing improvement, stability or worsening on each scale were reported, with a change of ≥10 points considered clinically meaningful (cm). ## Results: 255 patients completed baseline and ≥1 post-baseline pro assessment. most patients had cm improvement (42.4 %) or stable (38.0 %) scores for global qol. functioning domains with the greatest proportion of patients with improved scores were role (37.6 %) and emotional (36.9 %); only one domain had more patients showing worsening than improving function (cognitive [24.3 % vs 22.4 %]). most patients showed improve

Who reads Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer?

Author

Solange Peters; Alice T. Shaw; Benjamin Besse; Enriqueta Felip; Benjamin J. Solomon; Ross A. Soo; Alessandra Bearz; Shirish M. Gadgeel; Chia-Chi Lin; Steven Kao; Takashi Seto; Elizabeth T. Masters; Antonello Abbattista; Jill S. Clancy; Holger Thurm; Arlene Reisman; Gerson Peltz; D. Ross Camidge

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 0169-5002)

Published

2020

Language

EN

Field

Medicine (Health Sciences)